Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics (ECOTESTGER)

Creation of an Ecological Tool Assessing Episodic Memory in Geriatrics: an Adaptation of the Memory Test With Self-Initiated Items (MAI)

In this study the participants can be recruited via scheduled consultation and external institutions (associations, senior club..). Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.

Study test is ecological MAI. This test are assigned in two groups (with or without neurocognitive disorders).

Study Overview

• Status: Recruiting
• Conditions: Neurocognitive Disorders; Memory Disorders
• Intervention / Treatment: Diagnostic test: ecological MAI test

Detailed Description

In this study the participants can be recruited via scheduled consultation and external institutions (associations, senior club..). Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease.

Study test is ecological MAI. Participation will be 30 minutes for patients see in case of routine care and 2h30 for those accompanying the patients and participants recruited in external institutions.

Participants are assigned in two groups. Group 1 : with neurocognitive disorders Group 2 : without neurocognitive disorders

Benefits :

For participants without neurodegenerative disorder, study enables to take control early if anomaly will be detected.

The study permit to have cognitive assessment.

Risk : It's possible that participants feel tired. No constraints for participants seen during scheduled consultation.

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Brunhilde CANESSON; Phone Number: +33 03.21.69.16.36; Email: bcanesson@ch-lens.fr
• Study Contact Backup: Name: Mélanie VERLAY; Phone Number: +33 03.21.69.10.28; Email: mverlay@ch-lens.fr

Study Locations

• France
  • Lens, France, 62408
    • Recruiting
    • Centre Hospiralier de Lens
    • Contact: MELANIE VERLAY; Phone Number: 0601023068; Email: mverlay@ch-lens.fr
    • Principal Investigator: BRUNHILDE CANESSON

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 70 years and older (Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or female ≥ 70 ans
• Person have good locomotion, move independently
• Personne agree to participate

Groupe 1 : 17≤MMSE≤24 (GRECO) Diagnosis of neurodegenerative diseases (major neurocognitive disorders: Alzheimer, mixed dementia, lobar frontotemporal degeneration, vascular dementia).

Groupe 2 : MMSE ≥ à 25 (GRECO) Without neurodegenerative disease

Exclusion Criteria:

• Person with legal protective measures
• Person deprived of liberty
• Mental retardation or MMSE≤ 16
• Understanding verbal disorders
• Visual major disturbances
• Person with disease causing increased fatigue
• Person with psychiatric pathology excepted anxiety disorder or depression with mild episodes.
• Person not covered by French national health insurance

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Groupe 1 : with neurocognitive disorders; with neurocognitive disorders	Diagnostic test: ecological MAI test; Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease. Study test is ecological MAI.
Other: Groupe 2 : without neurocognitive disorders; without neurocognitive disorders	Diagnostic test: ecological MAI test; Neuropsychological assessment will be realize to determine presence or absence of neurodegenerative disease. Study test is ecological MAI.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare performance obtaining to overall score remind ecological MAI between older persons with neurocognitive disorders (groupe 1) and older persons without neurocognitive disorders (groupe 2).	Overall score remind ecological MAI test (0 to 12) in two groups.	day 1

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To compare between case and control the various dimensions of episodic memory: temporal component, space component and association component.	Spatial component is defined by localisation score. Score (0 to 12)	day 1
To compare between case and control the various dimensions of episodic memory: temporal component, space component and association component.	Temporal component is defined by temporal dimension. Score (0 to 12)	day 1
To compare between case and control the various dimensions of episodic memory: temporal component, space component and association component.	Association component is defined by binding score. Score (0 to 12)	day 1

Collaborators and Investigators

• Sponsor: Centre Hospitalier de Lens

Study record dates

Study Major Dates

• Study Start (Actual): March 8, 2023
• Primary Completion (Estimated): March 8, 2028
• Study Completion (Estimated): March 9, 2028

Study Registration Dates

• First Submitted: December 9, 2022
• First Submitted That Met QC Criteria: December 19, 2022
• First Posted (Actual): December 30, 2022

Study Record Updates

• Last Update Posted (Actual): May 8, 2026
• Last Update Submitted That Met QC Criteria: May 5, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: GERIATRICS
• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Mental Disorders; Neurobehavioral Manifestations; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Neurocognitive Disorders; Memory Disorders
• Other Study ID Numbers: 2022-02; 2022-A02139-34 (Other Identifier: ID-RCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No